In April 2023, the Japan Society of Hepatology published its official guidelines on liver rehabilitation for chronic liver disease. In this article, we summarize the current evidence on the role of liver rehabilitation in slowing the progression of chronic liver disease, particularly metabolic dysfunction-associated steatotic liver disease (MASLD), liver cirrhosis, and hepatocellular carcinoma (HCC). Specifically, we outline the following: (1) the definition of liver rehabilitation and its target population; (2) exercise therapy in liver rehabilitation according to disease state; (3) considerations for patients with complications; (4) nutritional therapy in liver rehabilitation; and (5) potential economic benefits. Liver rehabilitation represents a novel therapeutic approach for patients with chronic liver disease, and this guidance aims to promote high-quality clinical research and strengthen the evidence base for its application.
The optimal timing of surgery following neoadjuvant therapy in esophageal squamous cell carcinoma (ESCC) remains uncertain. This exploratory analysis aims to assess the impact of time to surgery (TTS) on perioperative and survival outcomes in patients with advanced ESCC enrolled in the phase III trial JCOG1109. Patients who underwent esophagectomy following neoadjuvant chemotherapy or chemoradiotherapy were included. Within each treatment arm, patients were categorized into four TTS subgroups according to cohort quartiles. Perioperative complications, overall survival (OS), and progression-free survival (PFS) were evaluated. The median TTS was 35 (range, 16–81), 38 (17–109), and 41 (14–98) days for the cisplatin plus fluorouracil (CF), docetaxel, cisplatin plus fluorouracil, and CF with radiotherapy (CF-RT) arms, respectively. Baseline characteristics were comparable across the TTS subgroups. Operative time and overall complication rates showed no significant differences. In the CF-RT arm, a longer TTS was associated with increased blood loss (200, 210, 300, and 370 mL) and a trend toward a higher anastomotic leakage (6
In skull-base surgery, excessive brain retraction may cause brain retraction injury (BRI), yet the brain retraction distance (BRD) that contributes to BRI and the potential of skull-base approaches to reduce BRD remain unclear. This study used a virtual reality (VR)–based method to quantify BRD related to BRI and to assess the impact of skull-base approaches on reducing BRD. We retrospectively analyzed 18 patients who underwent frontotemporal craniotomy for anterior skull-base tumors. Three-dimensional models were generated from perioperative imaging, and the frontal lobe was virtually elevated on the 3D model to reproduce the surgical exposure. BRD was estimated by comparing pre- and post-retraction configurations, and its association with BRI was assessed. Additionally, a virtual orbitotomy was performed to evaluate how much BRD could be reduced with this approach. Four patients developed BRI. The median BRD was 6.2 mm in the non-BRI group, whereas it was 12.2 mm in the BRI group, demonstrating a significant difference. Receiver operating characteristic curve analysis identified 10.1 mm as the optimal cutoff value for predicting BRI, yielding a sensitivity of 100
AIM:To evaluate fetal growth outcomes in gestational diabetes diagnosed before 20 weeks' gestation (E-GDM) following immediate intervention and to identify factors associated with abnormal fetal growth. METHODS:We retrospectively analyzed singleton term pregnancies with E-GDM between 2016 and 2021 at two university hospitals in Japan: Keio University Hospital (KUH) and Yokohama City University Medical Center (YCUMC). Dietary management was initiated immediately after diagnosis in both hospitals. At KUH, all E-GDM women underwent self-monitoring of blood glucose (SMBG). At YCUMC, the indication for SMBG was determined based on pre-pregnancy weight, the number of abnormal values on the oral glucose tolerance test, and other glycemic biomarkers, including HbA1c and glycated albumin. Fetal growth outcomes, assessed as the proportions of large-for-gestational-age (LGA) and small-for-gestational-age (SGA), were evaluated in E-GDM receiving early management. RESULTS:Among 509 pregnancies (190 at KUH and 319 at YCUMC), LGA and SGA were observed in 63 (12%) and 46 (9%), respectively. The proportion of LGA was not significantly associated with pre-pregnancy BMI (underweight, 9.6%; normal, 11%; overweight/obese, 16%: p = 0.20). In contrast, there was a significant difference in the proportion of SGA among the three groups (underweight, 19%; normal, 8.2%; overweight/obese, 7.2%: p = 0.024). Multivariate analysis demonstrated that pre-pregnancy underweight was significantly associated with SGA in comparison with pre-pregnancy normal weight. CONCLUSIONS:Fetal growth outcomes in E-GDM receiving early intervention were comparable to that of uncomplicated Japanese pregnancies. Since pre-pregnancy underweight remained a risk factor of SGA, clinicians should pay attention to the development of SGA in lean women with E-GDM.
OBJECTIVE:To investigate the long-term safety and efficacy of tocilizumab, an IL-6 receptor inhibitor, in patients with adult-onset Still's disease. METHODS:Patients who completed the precedent phase III trial of tocilizumab for adult-onset Still's disease were enrolled in a long-term extension (LTE) study. Patients received i.v. tocilizumab (8 mg/kg every 2 weeks) until its approval in Japan. The primary end point was safety and tolerability, and secondary endpoints included the ACR coreset response, glucocorticoid doses, tocilizumab dosing interval, remission defined as achieving ACR50 without fever and other laboratory parameters. Efficacy was assessed every 12 weeks. RESULTS:All 22 patients who had completed the precedent phase III trial participated in the LTE study. Sixteen (72.7%) completed the LTE study, with the mean observation period of 168.9 ± 10.8 weeks. Whereas three (13.6%) patients experienced serious adverse events, resulting in two patients withdrawn from the trial, no new safety signal was detected. Treatment efficacy was maintained through the LTE study, with the ACR70 response rate of 68.2% and 95.2% reduction in glucocorticoid doses from the start of the phase III trial and glucocorticoid-free remission of 40.9% at the last visit. Laboratory markers such as CRP and ferritin remained well controlled. The dosing interval was successfully extended in 63.6% of patients, with the overall mean tocilizumab interval at the final visit of 3.4 weeks. CONCLUSIONS:During the observation period, no new safety findings were observed with the long-term use of tocilizumab. Response to tocilizumab was sustained even with an extended dosing interval, with substantial glucocorticoid dose reduction or discontinuation. CLINICAL TRIAL REGISTRATION:UMIN000018414.